
News
Filter Results
Displaying 1–10 of 512
-
May 15, 2025
ARVO 2025 Highlight: J&J’s XLRP Gene Therapy Didn’t Meet Primary Endpoint in Phase 3 Clinical Trial
Despite missing the primary endpoint, the treatment improved vision for some patients.
-
May 13, 2025
The company is planning a Phase 2/3 clinical trial for the therapy in late 2025.
-
May 12, 2025
Part B of the trial will enroll nine adult patients as well as three pediatric patients.
-
May 9, 2025
The company is currently enrolling patients in its Phase 2/3 VISTA Clinical Trial.
-
May 1, 2025
The Foundation Fighting Blindness develops strategic partnership with Alma, a network of 25,000 mental health professionals dedicated to simplifying access to high-quality, affordable mental healthcare.
-
Apr 25, 2025
The Foundation Fighting Blindness and the Retinal Degeneration Fund (RD Fund) hosted their annual Investing in Cures Summit (ICS) on March 21 and 22, 2025 in Tampa to highlight the strong progress in development of treatments and cures for the entire spectrum of retinal degenerative diseases.
-
Apr 11, 2025
Age-Related Macular Degeneration Research Advances
Recent developments in research on age-related macular degeneration.
-
Apr 11, 2025
Leber Congenital Amaurosis Research Advances
Recent developments in research on Leber congenital amaurosis
-
Apr 11, 2025
Usher Syndrome Research Advances
Recent developments in research on Usher Syndrome.
-
Apr 11, 2025
Retinitis Pigmentosa Research Advances
Recent developments in research on retinitis pigmentosa.